These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 25284275)

  • 41. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.
    Bissonnette R; Bolduc C; Poulin Y; Guenther L; Lynde CW; Maari C
    J Am Acad Dermatol; 2010 Aug; 63(2):228-34. PubMed ID: 20494479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
    Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
    Elewski BE; Baker CS; Crowley JJ; Poulin Y; Okun MM; Calimlim B; Geng Z; Reyes Servin O; Rich PA
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):2168-2178. PubMed ID: 31304993
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.
    Chiricozzi A; Bianchi L; Zangrilli A; Bavetta M; Giunta A; Chimenti S; Saraceno R
    Eur J Dermatol; 2015; 25(1):64-9. PubMed ID: 25514606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
    Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
    Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW; Villanueva Quintero DG; Echeverría CM; Gu Y; Karunaratne M; Reyes Servín O
    Am J Clin Dermatol; 2016 Dec; 17(6):691-699. PubMed ID: 27815915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
    Cai L; Gu J; Zheng J; Zheng M; Wang G; Xi LY; Hao F; Liu XM; Sun QN; Wang Y; Lai W; Fang H; Tu YT; Sun Q; Chen J; Gao XH; Gu Y; Teixeira HD; Zhang JZ; Okun MM
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):89-95. PubMed ID: 27504914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.
    Poulin Y; Sheth P; Gu Y; Teixeira HD
    Dermatol Ther (Heidelb); 2014 Jun; 4(1):33-42. PubMed ID: 24488828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis.
    Chiu HY; Wang TS; Chang CY; Tsai TF
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):991-8. PubMed ID: 21812835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U; Kragballe K; Reich K; Griffiths CE; Gu Y; Wang Y; Rozzo SJ
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A; Bavetta M; Scaramella M; Bianchi L
    G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
    J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.